Assessment of patients with hereditary transthyretin amyloidosis : understanding the impact of management and disease progression
Main Author: | |
---|---|
Publication Date: | 2019 |
Other Authors: | , , , , , |
Format: | Article |
Language: | eng |
Source: | Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
Download full: | http://hdl.handle.net/10451/46443 |
Summary: | © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon inany way. |
id |
RCAP_706d330f2aebbce5e6aaa2bb89e9357a |
---|---|
oai_identifier_str |
oai:repositorio.ulisboa.pt:10451/46443 |
network_acronym_str |
RCAP |
network_name_str |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
repository_id_str |
https://opendoar.ac.uk/repository/7160 |
spelling |
Assessment of patients with hereditary transthyretin amyloidosis : understanding the impact of management and disease progressionATTRAmyloidosisFollow-upHereditaryMonitoringProgressionTransthyretin© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon inany way.Timely diagnosis of hereditary variant transthyretin (ATTRv) amyloidosis is critical for appropriate treatment and optimal outcomes. Significant differences are seen between patients receiving treatment and those who are not, though disease progression may continue despite treatment in some patients. Healthcare professionals caring for patients with ATTRv amyloidosis therefore need reliable ongoing assessments to understand the continuing course of disease and make appropriate treatment choices on an individual basis. Various signs and symptoms experienced by patients may be evaluated as indicators of disease progression, though there is currently no validated score that can be used for such ongoing assessment. Recognizing this situation, a group of clinicians highly experienced in ATTR amyloidosis developed an approach to understand and define disease progression in diagnosed and treated patients with ATTRv amyloidosis. The suggested approach is based on the recognition of distinct phenotypes which may usefully inform the particular tools, tests and investigations that are most likely to be appropriate for individual patients. It is aimed at implementing appropriate and ongoing assessment of patients being treated for ATTRv amyloidosis, such that the effectiveness of management can be usefully assessed throughout the course of disease and management can be tailored according to the patient’s requirements.Taylor & Francis GroupRepositório da Universidade de LisboaConceição, isabelCoelho, TeresaRapezzi, ClaudioParman, YeşimObici, LauraGalán, LucíaRousseau, Antoine2021-02-19T14:32:38Z20192019-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/46443engAmyloid. 2019 Sep;26(3):103-1111350-612910.1080/13506129.2019.1627312info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2025-03-17T14:28:36Zoai:repositorio.ulisboa.pt:10451/46443Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-29T03:12:58.281117Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse |
dc.title.none.fl_str_mv |
Assessment of patients with hereditary transthyretin amyloidosis : understanding the impact of management and disease progression |
title |
Assessment of patients with hereditary transthyretin amyloidosis : understanding the impact of management and disease progression |
spellingShingle |
Assessment of patients with hereditary transthyretin amyloidosis : understanding the impact of management and disease progression Conceição, isabel ATTR Amyloidosis Follow-up Hereditary Monitoring Progression Transthyretin |
title_short |
Assessment of patients with hereditary transthyretin amyloidosis : understanding the impact of management and disease progression |
title_full |
Assessment of patients with hereditary transthyretin amyloidosis : understanding the impact of management and disease progression |
title_fullStr |
Assessment of patients with hereditary transthyretin amyloidosis : understanding the impact of management and disease progression |
title_full_unstemmed |
Assessment of patients with hereditary transthyretin amyloidosis : understanding the impact of management and disease progression |
title_sort |
Assessment of patients with hereditary transthyretin amyloidosis : understanding the impact of management and disease progression |
author |
Conceição, isabel |
author_facet |
Conceição, isabel Coelho, Teresa Rapezzi, Claudio Parman, Yeşim Obici, Laura Galán, Lucía Rousseau, Antoine |
author_role |
author |
author2 |
Coelho, Teresa Rapezzi, Claudio Parman, Yeşim Obici, Laura Galán, Lucía Rousseau, Antoine |
author2_role |
author author author author author author |
dc.contributor.none.fl_str_mv |
Repositório da Universidade de Lisboa |
dc.contributor.author.fl_str_mv |
Conceição, isabel Coelho, Teresa Rapezzi, Claudio Parman, Yeşim Obici, Laura Galán, Lucía Rousseau, Antoine |
dc.subject.por.fl_str_mv |
ATTR Amyloidosis Follow-up Hereditary Monitoring Progression Transthyretin |
topic |
ATTR Amyloidosis Follow-up Hereditary Monitoring Progression Transthyretin |
description |
© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon inany way. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019 2019-01-01T00:00:00Z 2021-02-19T14:32:38Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10451/46443 |
url |
http://hdl.handle.net/10451/46443 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Amyloid. 2019 Sep;26(3):103-111 1350-6129 10.1080/13506129.2019.1627312 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Taylor & Francis Group |
publisher.none.fl_str_mv |
Taylor & Francis Group |
dc.source.none.fl_str_mv |
reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia instacron:RCAAP |
instname_str |
FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
collection |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
repository.name.fl_str_mv |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia |
repository.mail.fl_str_mv |
info@rcaap.pt |
_version_ |
1833601631205195776 |